...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30, 2019

Free
Due Dilligence

Potential Q4 2019 Events

Posted by: BearDownAZ on Oct 12, 2019 07:18AM
URL: https://agoracom.com/ir/Resverlogix/foru...-q4-2019-events/messages/2244940#message

Seeking Alpha: Resverlogix To Release Phase 3 Clinical Trial Data On A First-In-Class BET Bromodomain Inhibitor

Posted by: BearDownAZ on Sep 25, 2019 09:54AM
URL: https://seekingalpha.com/article/4293284...ta-first-class-bet-bromodomain-inhibitor

Resverlogix Publications and Posters

Also see NCBI PubMed list here: https://www.ncbi.nlm.nih.gov/pubmed/?term=%22apabetalone%22+OR+%22RVX-208%22

Posted by: BearDownAZ on Jun 06, 2019 10:04AM
URL: https://www.resverlogix.com/science-and-programs/publications
Resverlogix Corp. Links

Potential Q4 2019 Events

Posted by: BearDownAZ on Oct 12, 2019 07:18AM
URL: https://agoracom.com/ir/Resverlogix/foru...-q4-2019-events/messages/2244940#message

Seeking Alpha: Resverlogix To Release Phase 3 Clinical Trial Data On A First-In-Class BET Bromodomain Inhibitor

Posted by: BearDownAZ on Sep 25, 2019 09:54AM
URL: https://seekingalpha.com/article/4293284...ta-first-class-bet-bromodomain-inhibitor

Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease

Posted by: BearDownAZ on Sep 21, 2019 09:20PM
URL: https://www.sciencedirect.com/science/article/pii/S0021915019314765

Apabetalone Modulates Th1 Responses in Diabetes and CVD Through Intrinsic and Extrinsic Mechanisms: in vitro and in human study - EASD 2019 Poster

Posted by: BearDownAZ on Sep 17, 2019 09:58AM
URL: https://www.resverlogix.com/upload/media...2a/2019-9-9-easd-poster-2019---final.pdf

Epigenetics in CVD: A collection of PACE-CME symposium presentations Link #2

Posted by: BearDownAZ on Sep 04, 2019 12:48PM
URL: https://pace-cme.org/epigenetics-in-cvd/

Epigenetics in CVD: A collection of PACE-CME symposium presentations Link #1

Posted by: BearDownAZ on Sep 04, 2019 12:47PM
URL: https://pace-cme.org/browse/?k=VIDEO_IN_...|4725|4075|3874&h=Epigenetics%20in%20CVD

BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE Trial - ESC 2019 Poster

Posted by: BearDownAZ on Sep 04, 2019 12:35PM
URL: https://www.resverlogix.com/upload/media...9/2019-09-02-esc-design-poster-final.pdf

Apabetalone (RVX-208) Inhibits Key Drivers of Vascular Inflammation, Calcification, and Plaque Vulnerability Through a BET-dependent Epigenetic Mechanism - ESC 2019 Poster

Posted by: BearDownAZ on Sep 04, 2019 12:34PM
URL: https://www.resverlogix.com/upload/media...5f8e4/2019-09-03-esc-vi-poster-final.pdf

Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial

Posted by: BearDownAZ on Aug 14, 2019 06:43AM
URL: https://www.sciencedirect.com/science/article/abs/pii/S0002870319301978

Zacks SCR 8/5/19: Targeting September Readout for BETonMACE

Posted by: BearDownAZ on Aug 05, 2019 11:53AM
URL: https://s1.q4cdn.com/460208960/files/New...Research_08052019_T.RVX_Vandermosten.pdf